Liverpool Health Partners is delighted to announce the appointment of its new Chair, Professor Eliot Forster.
Prof Forster officially took up his post at the Academic Health Science System for Cheshire and Merseyside this month, following the decision by Dr Neil Goodwin CBE to stand down as Chair as part of his move into retirement.
Dr Dawn Lawson, Chief Executive of LHP, said: “I am delighted to welcome Prof Eliot Forster as our new Chair. Eliot has a wealth of experience both nationally and internationally which will help LHP develop into its next stage of evolution.
“We will refresh LHP’s strategy and level of ambition as part of our early work with Eliot. I am very much looking forward to the next stage of our journey.
“I would like to extend my sincere thanks to Dr Neil Goodwin for his leadership during a critical time of LHP’s development. LHP is now a solid organisation which is ambitious to develop further.”
Prof Forster is the Chief Executive Officer of F-star Therapeutics Inc, a clinical-stage biopharmaceutical company providing bispecific immune-oncology treatment.
Prof Forster said: “Since inception, Liverpool Health Partners have made a positive impact on the health of the population of Cheshire and Merseyside. This was brought into sharp focus during the coronavirus pandemic, where our partners proved the power of this collaboration in serving our community. Invaluable lessons were learned through first-hand research, and the beneficial impact on the management of Covid-19 were felt both locally and nationally.
“I would like to thank my predecessor Dr Goodwin for his generous guidance as I step into this role. I’m very much looking forward to bringing my experiences to the partnership and to build on the impressive achievements of LHP to date.
“With all of our partners, we’re perfectly placed to lead the way in our research, in education and to transform health outcomes for our local residents – working as one, for everyone.”
Prof Forster was the Founding Chairman of MedCity, which represents the life sciences cluster of London and the south east of England and is a Board member of the Office for the Strategic Coordination of Health Research. He has 30 years of experience in the pharmaceutical and biotechnology industry.
An alumnus of Liverpool University, where he is a Visiting Professor, he is also a Visiting Professor University of Pavia in Italy and a Fellow of the Royal Society of Medicine.